Top300 Bio CDMO - Facility Index and Biomanufacturers Subscription Database

The only Global Contract Development and Manufacturing Facilities Database subscription that actively tracks over 400+ dedicated CDMO facilities providing development and manufacturing services for biopharmaceuticals.

Hundreds of facilities manufacturing clinical and commercial scale biologics, account for $16.89 billion in services sales in 2023, growing at 17% annually.

Based on 30 years of evaluating and benchmarking the biopharmaceutical and life sciences industry, this database is updated continually and includes comprehensive information and insights.

"Top300 Bio CDMO Facility Index" ranks each 'dedicated' CDMO facility and provides regional quantitative analysis of biomanufacturing regions and clusters.

• Total bioreactor liter capacity
• CDMO/CMO service expertise
• Future Biomanufacturing capacity coming online
• Number of commercial and clinical biological products manufactured
• Revenue estimates
• Strengths and Challenges
• Technologies and expertise, and much more

USES FOR THE TOP300BIOCDMO.COM

• Identify your ideal CDMO or partners
• Identify specialized expertise such as cell or gene therapy, pDNA, mRNA
• Early-stage companies: sponsors can identify potential manufacturing partners
• Facility siting: Locate qualified employees; reduce hiring challenges
• Sales territory allocations: Determine where and how to staff territories
• Market Competition: Identify CDMO competitors' strengths and weaknesses
• Real estate valuation: For facilities, based on regional attractiveness
• HR and Recruiters: Looking for a critical mass of educated and skilled staff
• Industry Growth: Find where the industry is growing most rapidly
• Emerging Regions: CDMO Facilities in China, India, Latin America, Middle East regions
• CDMO Company Ranking: How do CDMO facilities rank, in skills, employment, capacity